Znanstveni rad - Izvorni znanstveni rad
Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review
Croatian Medical Journal, 61 (2020), 4; 326-332. https://doi.org/10.3325/cmj.2020.61.326

Gamulin, Marija; Nham, Eric; Rkman, Deni; Antunac, Zrna; Golubić, Zrna; Likić, Robert

Citirajte ovaj rad

Gamulin, M., Nham, E., Rkman, D., Antunac, Z., Golubić, Z. i Likić, R. (2020). Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review. Croatian Medical Journal, 61. (4), 326-332. doi: 10.3325/cmj.2020.61.326

Gamulin, Marija, et al. "Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review." Croatian Medical Journal, vol. 61, br. 4, 2020, str. 326-332. https://doi.org/10.3325/cmj.2020.61.326

Gamulin, Marija, Eric Nham, Deni Rkman, Zrna Antunac, Zrna Golubić i Robert Likić. "Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review." Croatian Medical Journal 61, br. 4 (2020): 326-332. https://doi.org/10.3325/cmj.2020.61.326

Gamulin, M., et al. (2020) 'Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review', Croatian Medical Journal, 61(4), str. 326-332. doi: 10.3325/cmj.2020.61.326

Gamulin M, Nham E, Rkman D, Antunac Z, Golubić Z, Likić R. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review. Croatian Medical Journal [Internet]. 01.08.2020. [pristupljeno 09.10.2024.];61(4):326-332. doi: 10.3325/cmj.2020.61.326

M. Gamulin, E. Nham, D. Rkman, Z. Antunac, Z. Golubić i R. Likić, "Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review", Croatian Medical Journal, vol. 61, br. 4, str. 326-332, Kolovoz 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:651557. [Citirano: 09.10.2024.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.